Zetia doesn't even move the needle.

Merck and Schering-Plough conducted several studies of their cholesterol treatment Zetia that raise questions about its risks to the liver but never published the results to those studies, The New York Times reports.

Trial results for an Amgen pipeline drug showed the biologic is comparable to existing therapies in its ability to boost bone density in women with cancer.

The FDA is failing to adequately police clinical trials, according to a report by the inspector general of the Department of Health and Human Services.

A worldwide Phase II trial of a Merck HIV vaccine was halted after an independent reviewer found the vaccine ineffective, the firm said.

An experimental drug from Eli Lilly reduced schizophrenia symptoms in a clinical trial of 200 patients, according to a paper published in the journal Nature.

Mercks Cordaptive, an extended-release niacin combined with a flushing inhibitor, has been filed for approval with the FDA, the firm said.

In an opinion piece yesterday, the chair of the FDA advisory committee on Avandia recommended the agency change the way it evaluates experimental diabetes drugs.

New data that support using higher doses of Lipitor may provide another plank in Pfizers strategy to drive sales during its best-selling drugs sunsetting patent window.

Merck’s experimental medication MK-0974 showed promising results in migraine patients who weren’t helped by standard treatments, according to the findings of a Merck–funded Phase II study.